HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Clinical trials for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy-Chemo combo shows promise in aggressive lymphoma trial
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can improve outcomes for people with aggressive B-cell non-Hodgkin lymphoma. About 30 participants will receive the combination, followed by a short course of nivolumab…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Apr 29, 2026 00:51 UTC
-
New combo aims to extend life for elderly lymphoma patients
Disease control OngoingThis study looks at whether adding an oral drug (CC-486) to standard chemotherapy (R-miniCHOP) can help people aged 75 and older with newly diagnosed aggressive B-cell lymphomas live longer without their cancer returning. About 422 participants will receive either the standard tr…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 29, 2026 00:49 UTC